Payment overview · 2025
General Payments
$1,531.91
61 reported records · 22 companies
Healthcare provider profile · identity verified
Vikram Kapur, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · AVONDALE, AZ · NPI 1063466647
Verified facts
What the public records show
CMS Open Payments records show Vikram Kapur, M.D received $1,531.91 in general payments during 2025 across 61 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $326.79 | 21.3% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $199.42 | 13.0% | 13 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $159.60 | 10.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $123.42 | 8.1% | 7 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $110.08 | 7.2% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.48 | 6.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $72.53 | 4.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.66 | 3.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.37 | 3.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.43 | 2.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.85 | 2.4% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $31.51 | 2.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.28 | 1.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $25.59 | 1.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $25.58 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.35 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.16 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.80 | 1.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $18.88 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.32 | 1.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.62 | 1.1% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.19 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,531.91 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $311.43 | 6 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $159.38 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $123.42 | 7 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $110.08 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $102.48 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $72.53 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $55.66 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.43 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.04 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $35.41 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.32 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $35.03 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $31.51 | 2 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $25.58 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $18.88 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.19 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 349 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 229 | 88 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 177 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 65 |
| Gabapentin | Gabapentin | 166 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 26 |
| Amlodipine Besylate | Amlodipine Besylate | 142 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 41 |
| Losartan Potassium | Losartan Potassium | 109 | 41 |
| Metformin Hcl | Metformin Hcl | 102 | 34 |
| Ozempic | Semaglutide | 98 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 44 |
| Azithromycin | Azithromycin | 89 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 24 |
| Meloxicam | Meloxicam | 75 | 30 |
| Prednisone | Prednisone | 75 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 27 |
| Ibuprofen | Ibuprofen | 65 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Lisinopril | Lisinopril | 61 | 21 |
| Trazodone Hcl | Trazodone Hcl | 60 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 42 |
| Glimepiride | Glimepiride | 56 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 14 |
| Linzess | Linaclotide | 50 | 12 |
| Potassium Chloride | Potassium Chloride | 50 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 18 |
| Farxiga | Dapagliflozin Propanediol | 49 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 20 |
| Jardiance | Empagliflozin | 48 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 19 |
| Furosemide | Furosemide | 45 | 17 |
| Omeprazole | Omeprazole | 44 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 15 |
| Methylprednisolone | Methylprednisolone | 41 | 37 |
| Mounjaro | Tirzepatide | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 13 |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Estradiol | Estradiol | 36 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 14 |
| Lidocaine | Lidocaine | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 14 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Simvastatin | Simvastatin | 27 | 11 |
| Nystatin | Nystatin | 25 | 11 |
| Montelukast Sodium | Montelukast Sodium | 24 | 12 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 11 |
| Metronidazole | Metronidazole | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 13 |
| Hydrocortisone | Hydrocortisone | 19 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,531.91 · 61 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AJOVY, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, FANAPT, FREESTYLE LIBRE 3, Fluad, Flucelvax, General - Therapies, KRYSTEXXA, Korlym, LINZESS, LifeVest, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SPRAVATO, TONMYA, TRELEGY ELLIPTA, VRAYLAR, Veozah, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error